Synthetic analogs having the activity of naturally occurring forms of
申请人:——
公开号:US03974187A1
公开(公告)日:1976-08-10
Synthetic 2,3-dimethoxy-5-methyl-1,4-benzoquinone is converted into a series of new 6-alkyl derivatives. These 6-alkyl derivatives have straight carbon chains which are both saturated and unsaturated. The unsaturated derivatives contain one, two, three and four double bonds. These new synthetic quinones are analogs of the naturally occurring forms of coenzyme Q and have the same fundamental electron-transfer capacity of the natural forms of coenzyme Q. Although the degree of the activity of these new synthetic analogs differ, some of these new synthetic analogs are effective substitutes for the natural forms of coenzyme Q.
SMALL MOLECULE INHIBITION FOR PREVENTING OR TREATING FIBROTIC DISEASES
申请人:THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
公开号:US20190160050A1
公开(公告)日:2019-05-30
The present invention provides methods for preventing or treating a fibrotic disease in a subject. In some embodiments, the fibrotic disease is fatty liver disease, non-alcoholic fatty liver disease, or non-alcoholic steatohepatitis. In particular aspects, the methods comprise administering a small molecule inhibitor of Shc to achieve pharmacological suppression of Shc protein activity in the subject.
US3974187A
申请人:——
公开号:US3974187A
公开(公告)日:1976-08-10
[EN] SMALL MOLECULE INHIBITION FOR PREVENTING OR TREATING FIBROTIC DISEASES<br/>[FR] INHIBITION DE PETITES MOLÉCULES DANS LA PRÉVENTION OU LE TRAITEMENT DES MALADIES FIBROTIQUES
申请人:UNIV CALIFORNIA
公开号:WO2018026442A1
公开(公告)日:2018-02-08
The present invention provides methods for preventing or treating a fibrotic disease in a subject. In some embodiments, the fibrotic disease is fatty liver disease, non-alcoholic fatty liver disease, or non-alcoholic steatohepatitis. In particular aspects, the methods comprise administering a small molecule inhibitor of Shc to achieve pharmacological suppression of Shc protein activity in the subject.